CPT 82523: Collagen Cross-Links Assay for Bone Resorption

CPT code 82523 represents a clinical laboratory assay for collagen cross-links, stable biomarkers of bone resorption used to monitor osteoporosis and osteopenia. Nationally, this test supports clinical decision-making about bone-loss rate and treatment effectiveness and is relevant to clinicians managing metabolic bone disease, endocrinology, geriatrics, and primary care practices that monitor therapy response. Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will find a concise overview of the clinical purpose of the assay, typical sites of service, and which major payers cover the service. The publication also summarizes common billing modifiers and the testing context for performance benchmarking and policy review. Clinical context covers how collagen cross-links serve as reliable serum and urine markers for bone resorption and why they are used in longitudinal monitoring of osteoporosis and osteopenia. Policy and billing sections provide national-level guidance on coverage considerations and documentation practices relevant to laboratory billing, while benchmark and payer-overview sections identify common coverage patterns and variations across major payers.

This summary is written for a national audience of clinicians, laboratory managers, and billing professionals seeking a clear, policy-focused explanation of CPT code 82523 and its role in monitoring bone health.

Billing Code Overview

CPT code 82523 describes a laboratory assay that measures collagen cross-links, biochemical markers used to assess bone resorption. The test assists clinicians in monitoring the rate of bone loss and evaluating treatment effectiveness for patients with osteoporosis and osteopenia.

Service Type: Clinical laboratory diagnostic test for bone metabolism

Typical Site of Service: Clinical laboratory or outpatient specimen collection site

Data not available in the input.

Clinical Context

A 68-year-old female with a history of postmenopausal osteoporosis is seen in an outpatient metabolic bone clinic for treatment monitoring. She was started on bisphosphonate therapy 12 months ago. The clinician orders a serum or urine biochemical marker test that measures collagen cross-links to evaluate bone resorption and determine treatment effectiveness. The patient presents to the clinical laboratory or outpatient phlebotomy unit where a blood sample (or timed urine collection) is obtained. The laboratory analyst performs the collagen cross–linking assay and generates a quantitative result reported to the ordering clinician. Results are reviewed during follow-up to assess ongoing fracture risk and to decide on continuation or modification of osteoporosis therapy.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	When reporting only the professional interpretation of a lab test result (if separated).
`TC`	Technical component	When reporting only the technical component (laboratory processing) of the test.

Taxonomy Code	Specialty	Notes
208000000X	Endocrinology, Diabetes & Metabolism	Specialists who manage metabolic bone disease and order bone turnover markers.
207RC0000X	Rheumatology	Rheumatologists treat osteoporosis and monitor bone-resorption markers.
207Q00000X	Internal Medicine	Primary care physicians or internists commonly order and follow laboratory monitoring.
363L00000X	Clinical Laboratory	Laboratory directors/analysts who perform and report the assay.
207K00000X	Obstetrics & Gynecology	Gynecologists may manage postmenopausal osteoporosis and order tests.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`M81.0`	Age-related osteoporosis without current pathological fracture	Common indication for monitoring bone turnover markers to assess bone resorption and treatment response.
`M80.00`	Age-related osteoporosis with current pathological fracture, unspecified site	Bone resorption markers may be evaluated when fractures occur to assess disease activity.
`M85.8`	Other specified disorders of bone density and structure	Used for atypical bone density disorders where turnover markers help characterize bone metabolism.
`E03.9`	Hypothyroidism, unspecified	Thyroid disease can affect bone turnover; clinicians may monitor markers when managing bone health.
`M81.8`	Other osteoporosis without current pathological fracture	General osteoporosis diagnosis for which bone resorption assays are utilized.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`82523`	Collagen cross-links (e.g., pyridinoline, deoxypyridinoline) assay	Primary test measuring bone resorption markers used to monitor osteoporosis therapy.
`83036`	Hemoglobin; glycosylated (A1c)	Common concurrent laboratory test in clinic visits for metabolic assessment, not specific to bone but often ordered in older patients with comorbid diabetes.
`82043`	Parathyroid hormone (PTH)	Evaluates calcium metabolism; often ordered alongside bone turnover markers when assessing osteoporosis.
`82310`	Vitamin D; 25-hydroxyvitamin D	Frequently ordered to assess vitamin D status as part of osteoporosis evaluation and management.
`81002`	Urinalysis, non-automated, without microscopy	May be performed if urine-based collagen cross-link assay is ordered to verify sample quality or concurrent evaluation.

OpenPayer

Summary & Overview